Company Filing History:
Years Active: 2025
Title: Thomas Tørring: Innovator in Cancer Treatment
Introduction
Thomas Tørring is a notable inventor based in Højbjerg, Denmark. He has made significant contributions to the field of cancer treatment through his innovative research and development of macrocyclic compounds. His work focuses on addressing the challenges posed by hypoxic cancer cells, which are often resistant to conventional therapies.
Latest Patents
Thomas Tørring holds a patent for "Macrocycles comprising a 4-amido-2,4-pentadienoate moiety for the treatment of hypoxic cancers." This patent describes macrocyclic compounds that include a 4-amido-2,4-pentadienoate (APD) moiety. The compounds are designed to exhibit selective toxicity to the hypoxic micro-environments commonly found in cancerous tissues. This innovative approach makes the disclosed compounds suitable for the treatment of hypoxic cancer cells.
Career Highlights
Thomas Tørring is affiliated with Aarhus Universitet, where he continues to advance his research in cancer treatment. His work has garnered attention for its potential to improve therapeutic outcomes for patients suffering from hypoxic cancers. With a focus on developing targeted therapies, Tørring's contributions are paving the way for new treatment options.
Collaborations
Thomas Tørring collaborates with esteemed colleagues, including Thomas Bjørnskov Poulsen and Per Hjerrild. These partnerships enhance the research efforts and broaden the impact of their collective work in the field of cancer treatment.
Conclusion
Thomas Tørring is a dedicated inventor whose work in developing macrocyclic compounds represents a significant advancement in the treatment of hypoxic cancers. His innovative approach and collaboration with fellow researchers highlight the importance of targeted therapies in improving patient outcomes.